242 related articles for article (PubMed ID: 29042204)
1. Antibody response to human papillomavirus vaccination and natural exposure in individuals with Fanconi Anemia.
Mehta PA; Sauter S; Zhang X; Davies SM; Wells SI; Myers KC; Panicker G; Unger ER; Butsch Kovacic M
Vaccine; 2017 Dec; 35(48 Pt B):6712-6719. PubMed ID: 29042204
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.
Robbins HA; Waterboer T; Porras C; Kemp TJ; Pawlita M; Rodriguez AC; Wacholder S; Gonzalez P; Schiller JT; Lowy DR; Esser M; Matys K; Poncelet S; Herrero R; Hildesheim A; Pinto LA; Safaeian M
Hum Vaccin Immunother; 2014; 10(10):2965-74. PubMed ID: 25483632
[TBL] [Abstract][Full Text] [Related]
3. In RRP, serologic response to HPV is frequently absent and slow to develop.
Buchinsky FJ; Ruszkay N; Valentino W; Derkay CS; McClay JE; Bastian RW; Myer CM; Lollar KW; Guris D
PLoS One; 2020; 15(3):e0230106. PubMed ID: 32160246
[TBL] [Abstract][Full Text] [Related]
4. Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes.
Alter BP; Giri N; Pan Y; Savage SA; Pinto LA
Vaccine; 2014 Feb; 32(10):1169-73. PubMed ID: 24295807
[TBL] [Abstract][Full Text] [Related]
5. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.
Safaeian M; Porras C; Schiffman M; Rodriguez AC; Wacholder S; Gonzalez P; Quint W; van Doorn LJ; Sherman ME; Xhenseval V; Herrero R; Hildesheim A;
J Natl Cancer Inst; 2010 Nov; 102(21):1653-62. PubMed ID: 20944077
[TBL] [Abstract][Full Text] [Related]
6. A Bivariate Mixture Model for Natural Antibody Levels to Human Papillomavirus Types 16 and 18: Baseline Estimates for Monitoring the Herd Effects of Immunization.
Vink MA; Berkhof J; van de Kassteele J; van Boven M; Bogaards JA
PLoS One; 2016; 11(8):e0161109. PubMed ID: 27537200
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica.
Coseo S; Porras C; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Wang SS; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M;
Sex Transm Dis; 2010 Nov; 37(11):706-14. PubMed ID: 20661178
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.
Scherpenisse M; Schepp RM; Mollers M; Meijer CJ; Berbers GA; van der Klis FR
PLoS One; 2013; 8(9):e74797. PubMed ID: 24058629
[TBL] [Abstract][Full Text] [Related]
9. HPV Serology Testing Confirms High HPV Immunisation Coverage in England.
Mesher D; Stanford E; White J; Findlow J; Warrington R; Das S; Pebody R; Borrow R; Soldan K
PLoS One; 2016; 11(3):e0150107. PubMed ID: 26959232
[TBL] [Abstract][Full Text] [Related]
10. First-void urine as a non-invasive liquid biopsy source to detect vaccine-induced human papillomavirus antibodies originating from cervicovaginal secretions.
Van Keer S; Willhauck-Fleckenstein M; Pattyn J; Butt J; Tjalma WAA; Van Ostade X; Hens N; Van Damme P; Waterboer T; Vorsters A
J Clin Virol; 2019 Aug; 117():11-18. PubMed ID: 31129514
[TBL] [Abstract][Full Text] [Related]
11. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
Goggin P; Sauvageau C; Gilca V; Defay F; Lambert G; Mathieu-C S; Guenoun J; Comète E; Coutlée F
Hum Vaccin Immunother; 2018 Jan; 14(1):118-123. PubMed ID: 29049007
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.
Heijstek MW; Scherpenisse M; Groot N; Tacke C; Schepp RM; Buisman AM; Berbers GA; van der Klis FR; Wulffraat NM
Ann Rheum Dis; 2014 Aug; 73(8):1500-7. PubMed ID: 23723319
[TBL] [Abstract][Full Text] [Related]
13. Skin and mucosal human papillomavirus seroprevalence in persons with Fanconi Anemia.
Katzenellenbogen RA; Carter JJ; Stern JE; Butsch Kovacic MS; Mehta PA; Sauter SL; Galloway DA; Winer RL
Clin Vaccine Immunol; 2015 Apr; 22(4):413-20. PubMed ID: 25651924
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
15. Prevaccine era human papillomavirus types 6, 11, 16 and 18 seropositivity in the U.S.A., National Health and Nutrition Examination Surveys, 2003-2006.
Introcaso CE; Dunne EF; Hariri S; Panicker G; Unger ER; Markowitz LE
Sex Transm Infect; 2014 Sep; 90(6):505-8. PubMed ID: 24748563
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial.
Gray P; Kann H; Pimenoff VN; Eriksson T; Luostarinen T; Vänskä S; Surcel HM; Faust H; Dillner J; Lehtinen M
PLoS Med; 2021 Jun; 18(6):e1003588. PubMed ID: 34097688
[TBL] [Abstract][Full Text] [Related]
17. Empirical sample-specific approaches to define HPV16 and HPV18 seropositivity in unvaccinated, young, sexually active women.
Ng K; Morais S; Wissing MD; Burchell AN; Tellier P-P; Coutlée F; Waterboer T; El-Zein M; Franco EL
Microbiol Spectr; 2024 Jun; 12(6):e0022924. PubMed ID: 38687066
[TBL] [Abstract][Full Text] [Related]
18. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E
Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097
[TBL] [Abstract][Full Text] [Related]
19. Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.
Safaeian M; Sampson JN; Pan Y; Porras C; Kemp TJ; Herrero R; Quint W; van Doorn LJ; Schussler J; Lowy DR; Schiller J; Schiffman MT; Rodriguez AC; Gail MH; Hildesheim A; Gonzalez P; Pinto LA; Kreimer AR;
J Natl Cancer Inst; 2018 Feb; 110(2):205-12. PubMed ID: 28954299
[TBL] [Abstract][Full Text] [Related]
20. [Vaccination against HPV in adults].
Gil Á
Rev Esp Quimioter; 2009 Nov; 22 Suppl 1():22-5. PubMed ID: 20084345
[No Abstract] [Full Text] [Related]
[Next] [New Search]
